Over the years, United States drug manufacturers have assumed an increasingly significant role in reporting across a broad range of federal and state programs. As regulatory expectations continue to expand, the reporting landscape has grown more complex. Although federal and state reporting programs share the common goal of oversight, they differ in both purpose and scope. Federal reporting requirements are generally tied to the calculation of rebates, pricing benchmarks, and payment obligations under contracts and government programs, while state reporting requirements tend to emphasize public accountability, often requiring manufacturers to justify high launch prices or significant price increases.

The Expanding Patchwork of State and Federal Reporting

Drug manufacturers are subject to dozens of federal reporting requirements, surveillance systems, and compliance programs, primarily overseen by the FDA, CMS, and HRSA. Collectively, these programs address areas such as safety, manufacturing quality, pricing, and distribution. While federal requirements are generally more standardized, state reporting obligations remain an important and growing part of the compliance landscape. These requirements vary significantly by jurisdiction and often focus on issues such as high launch prices, price-justification reporting related to significant Wholesale Acquisition Cost (WAC) increases, supply chain transparency, and increasing oversight of the 340b program.

Although HRSA administers the federal 340b program, limited public reporting at the federal level has prompted increased action by states. State 340b oversight often operates alongside broader drug pricing and transparency initiatives, including requirements for manufacturers to report rebates paid to pharmacy benefit managers (PBMs), disclose Wholesale Acquisition Cost (WAC) pricing information, and support improvements to state data systems. These efforts are intended, in part, to help prevent “duplicate discounts,” which occur when a manufacturer provides both a 340b discount and a Medicaid rebate on the same drug product.

Currently, federal policymakers are considering proposals such as the SUSTAIN 340B Act and the 340b ACCESS Act, both of which seek to strengthen transparency and reporting related to how 340b savings are used. In the absence of federal action, however, states are moving ahead with their own requirements and, in doing so, are setting an important precedent. More than a dozen states have recently adopted or advanced 340b related reporting requirements, often in connection with broader contract pharmacy or pharmacy access laws, to better understand how program savings are being used. Arkansas was among the first states to enact legislation linking 340b oversight with transparency expectations, and other states have followed. Of particular interest are Washington’s recent updates to its transparency framework. Washington’s new law adds an annual 340b reporting requirement for drug manufacturers and also requires certain covered entities to submit annual information related to their participation in the 340b program. This change amends the state’s existing price transparency statutes and adds to the complexity of manufacturer reporting obligations.

Reporting to multiple federal and state agencies places a substantial administrative burden on drug manufacturers. State price transparency statutes often require manufacturers to track a wide range of data elements, including financial information, patient population data, product launch dates, state distribution licensure, and sales representative activity. As 340b requirements are incorporated into these frameworks, manufacturer reporting obligations will expand further. In Washington, for example, manufacturers would be required to report the number of 340b units distributed to covered entities and contract pharmacies within the state, the aggregate discounts provided by drug to those entities, and the average 340b discount for each of the top 25 340b drugs dispensed in the state, including the percentage of the discount attributable to inflationary rebates.  However, two pharmaceutical giants, AbbVie and Novartis have brought lawsuits against the state alleging this new law to tamp down prescription drug prices for hospitals won’t result in discounts for patients.

Building the Infrastructure for Compliance Agility

As compliance requirements grow more complex, tracking and managing them has become a central challenge for drug manufacturers. The continually evolving landscape; including state price transparency laws, 340b requirements, drug utilization review boards, and prescription drug affordability boards, demands significant resources and specialized expertise to maintain compliance effectively.  As a result, drug manufacturers must invest in stronger compliance infrastructure and cross-functional coordination to keep pace with an increasingly fragmented and demanding reporting environment. Without a unified reporting framework, manufacturers will continue to face growing operational strain as they navigate overlapping and often inconsistent requirements across jurisdictions.

As federal and state reporting obligations intensify, pharmaceutical manufacturers must transition from reactive compliance to proactive operational agility. Fragmented tracking methods no longer suffice in an era of rapid legislative shifts. Organizations that centralize regulatory intelligence and harmonize internal data structures will mitigate risk, protect market access, and maintain a competitive advantage.

Navigating the labyrinth of evolving state and federal reporting mandates is not a journey drug manufacturers should undertake alone. As regulatory complexity intensifies, the margin for error shrinks, making the insights of an experienced industry advisor an invaluable asset for sustained operational success. Partnering with a dedicated compliance professional ensures your organization shifts from a defensive, reactive posture to a strategic, proactive model allowing for anticipation of legislative pivots rather than merely responding to them. By securing trusted external guidance, leadership can confidently mitigate risk, safeguard market access, and protect the organization's reputation, leaving teams free to focus on driving core commercial innovation.

IntegriChain's regulatory and market access experts help pharmaceutical manufacturers build the reporting infrastructure needed to navigate today's complex federal and state compliance landscape. Contact us today to learn how IntegriChain can support your compliance strategy bjensen@integrichain.com